Early detection allows for early treatment for saving and improving patients' lives. Bio-Rad's instruments and controls for HIV testing provide a convenient way to check off the steps in your HIV Testing Algorithm.
Contact a Bio-Rad sales representative today.
BioPlex 2200 HIV Ag‐Ab Assay5th Generation
The BioPlex 2200 HIV Ag‐Ab multiplex immunoassay helps you perform the first step of the HIV Testing Algorithm. The assay helps identify HIV‐1 and HIV‐2 infection and acute HIV‐1infection through the detection of HIV‐1 and HIV‐2 antibodies and HIV‐1 p24 antigen.
Thanks to its high sensitivity for HIV‐1 p24 Ag detection and ability to differentiate between HIV‐1 and HIV‐2 antibodies, the HIV Ag‐Ab multiplex assay detects early acute infections and guides in the choice of supplemental testing through the HIV testing algorithm.
BioPlex 2200 Multiplexing Technology
4 Individual Results
GS HIV Combo Ag/Ab EIA
The GS HIV Combo Ag/Ab EIA Kit paired with the EVOLIS System for full EIA automation offers you another screening option to perform the first step of the HIV Testing Algorithm.
GS HIV Combo Ag/Ab Kit
Ideal for low to high volume EIA testing using the PR4100 and PW41 standalone microplate reader and washer or EVOLIS System for full automation, the GS HIV Combo Ag/Ab EIA Kit helps close the window on acute HIV infection with increased sensitivity and specificity.
Simultaneous antigen/antibody detection by EIA
Whether you prefer multiplex technology or traditional EIA testing, Bio-Rad offers the assay you need to perform the first step of the HIV Testing Algorithm.
The Geenius HIV 1/2 Supplemental Assay is designed to test specimens with a reactive HIV Ag/Ab immunoassay result (or repeatedly reactive, if repeat testing is recommended by manufacturer) determined in Step 1 of the HIV Testing Algorithm.
The Geenius HIV 1/2 Supplemental Assay is the only FDA-approved test for the confirmation and differentiation of antibodies to HIV‐1 and HIV‐2, as required in the second step of the CDC HIV Testing Algorithm.
Note: Specimens that are reactive in the HIV Ag/Ab screen and non‐reactive or indeterminate in the HIV‐1/HIV‐2 Ab differentiation test should be tested with an FDA-approved HIV‐1 nucleic acid test.
The role of the diagnostic laboratory in providing reliable test results is a key component in controlling the spread of infection.
Reporting false negative results can be just as devastating as reporting false positive results when it comes to the treatment and personal lifestyle changes affecting patients.
Using Bio-Rad VIROTROL HIV controls for an unbiased, independent assessment of your testing systems helps to provide additional confidence in your test results.
Bio-Rad quality control solutions feature QC products, data management tools, and services covering hundreds of analytes and thousands of methods.
BRiCare Support and Monitoring
Bio-Rad's instrument monitoring application for remote service and support. BRiCare is available for all of Bio-Rad's diagnostic instruments for continuous monitoring and remote sessions with an instrument's computer.
1. Centers for Disease Control and Prevention and Association of Public Health Laboratories (2014). Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://stacks.cdc.gov/view/cdc/23447. Accessed August 14, 2019.
2. National Center for Health Statistics (US). Health, United States (2017).Table 34, Human immunodeficiency virus (HIV) diagnoses, by year of diagnosis and selected characteristics: United States, 2011-2016.Available from: https://www.cdc.gov/nchs/data/hus/2017/034.pdf. Accessed August 14, 2019.